NEW YORK (Legal Newsline) — A shareholder has filed a class action lawsuit against a bio-pharmaceutical company and its executives, alleging violation of federal law.
Kenneth Walsh filed a complaint, individually and on behalf of all others similarly situated, Feb. 8 in U.S. District Court for the Southern District of New York against Stemline Therapeutics, Inc. and executives Ivan Bergstein and David Gionco, alleging they issued false and misleading statements to the public.
According to the complaint, Walsh suffered damages from purchasing Stemline securities at inflated prices. The alleges the defendants issued false and misleading statements in order to artificially inflate the company's securities prices.
Walsh seeks trial by jury, damages, interest, all legal fees and all other relief the court deems just. He is represented by attorneys Jeremy A. Lieberman, J. Alexander Hood II and Hui M. Chang of Pomerantz LLP in New York, and by Patrick Dahlstrom of Pomerantz in Chicago.
U.S. District Court for the Southern District of New York Case number 1:17-cv-00940-UA